Secondary Progressive Multiple Sclerosis (SPMS)

Secondary Progressive Multiple Sclerosis (SPMS) is the indication for 5 drugs in DrugBank. It is covered by 5 curated, structured indications.

Also known as: Secondary Progressive Multiple Sclerosis · Multiple Sclerosis, Secondary Progressive · Secondary Progressive MS (SPMS) · Secondary-progressive Multiple Sclerosis · Secondary Progressive MS
Classified under: Encephalopathy
Immune System Diseases
Nervous System Diseases
Signs, Symptoms, and General Pathologies
Indicated drugs: Alemtuzumab
Interferon beta-1b
Mitoxantrone
Natalizumab
Peginterferon beta-1a

Resolves to

Vocabularies

MeSHM0334287SNOMED CT425500002MedDRA10063400UMLSC0751965

What you can answer from here — as of October 25, 2026

5Indicated drugsWith each drug's targets and mechanism

Listed above

5Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

86Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for Secondary Progressive Multiple Sclerosis (SPMS) share a target, and which companies have late-stage candidates against it?

Create a free account or log in to explore the full data card.